In this case series, patients with small-duct-predominant iCCA, particularly those harboring IDH1/2 mutations or FGFR2 fusions, exhibited longer progression-free survival (PFS), supporting the use of targeted therapies such as ivosidenib and pemigatinib, both of which are approved for advanced cholangiocarcinoma [16,17]. This evidence concerns the gene FGFR2 and cholangiocarcinoma.